What topical ointment is most appropriate for managing mild-to-moderate eczema and plaque psoriasis?

Best Topical Ointment for Eczema and Psoriasis

For eczema, use potent topical corticosteroids (TCS) or tacrolimus 0.1% as first-line treatment; for psoriasis, use the combination of calcipotriene/betamethasone dipropionate ointment as the single most effective topical therapy. These recommendations are based on the highest quality evidence showing superior efficacy for both conditions 1, 2, 3.

For Eczema (Atopic Dermatitis)

First-Line Treatment Options

The 2025 AAD guidelines and 2024 Cochrane network meta-analysis establish a clear hierarchy of effectiveness 1, 3:

Most Effective Agents:

• Potent TCS (Class II-III) - Ranked among the most effective with moderate confidence
• Tacrolimus 0.1% - Equally effective to potent TCS (OR 6.27 for symptom control, OR 8.06 for clinical signs) 3
• Ruxolitinib 1.5% (JAK inhibitor) - Similar efficacy to potent TCS and tacrolimus 0.1% 3

Newer FDA-Approved Options (2024-2025):

• Tapinarof cream 1% - Nonsteroidal aryl hydrocarbon receptor agonist, approved December 2024, shows moderate improvement with excellent tolerability 1
• Roflumilast cream 0.15% - PDE-4 inhibitor, approved July 2024 for mild-to-moderate disease, effective at 4 weeks 1

Treatment Algorithm for Eczema

1. Initial therapy (2-4 weeks): Start with potent TCS or tacrolimus 0.1% for moderate-to-severe disease
2. Mild disease: Moderate TCS or roflumilast 0.15%
3. Maintenance: After achieving control, transition to proactive intermittent application or reactive as-needed treatment 1
4. Application site concerns: If TCS cause irritation, switch to tacrolimus 0.1% (though note: tacrolimus has higher application-site reaction rates - OR 2.2) 3

Critical Caveats for Eczema Treatment

• Avoid mild TCS and PDE-4 inhibitors (roflumilast, crisaborole) for initial treatment of moderate-to-severe disease - they consistently ranked among the least effective 3
• Tapinarof 1% ranked among the least effective in 3 of 5 efficacy networks despite recent approval 3
• Application-site reactions are most common with tacrolimus 0.1% (OR 2.2), crisaborole 2% (OR 2.12), and pimecrolimus 1% (OR 1.44), but least common with TCS 3

For Psoriasis

First-Line Treatment: Combination Therapy

Calcipotriene/betamethasone dipropionate combination products are the single most effective topical treatment for psoriasis 2:

• Strength of recommendation: A (highest level)
• Evidence: 69-74% of patients achieved clear/almost clear status at 52 weeks with once or twice daily application 2
• Superior to monotherapy: More effective than either calcipotriene or betamethasone alone for 3-52 weeks 2
• Long-term safety: No serious adverse events, striae, or HPA axis suppression observed over 52 weeks 2

Alternative Regimens for Psoriasis

If combination product unavailable:

• Potent/very potent TCS alone (Class I-III) - Effective for up to 4 weeks, efficacy rates 58-92% 2
• Sequential therapy: High-potency TCS twice daily on weekends + vitamin D analogues twice daily on weekdays (Strength B) 2
• Split application: Morning high-potency TCS + evening vitamin D analogues (Strength B) 2

For specific anatomic sites:

• Scalp: Calcipotriene foam or calcipotriene/betamethasone gel for 4-12 weeks (Strength A) 2
• Face/intertriginous areas: Tacalcitol ointment or calcipotriene + hydrocortisone for 8 weeks (Strength B) 2
• Nails: Vitamin D analogues + betamethasone dipropionate 2

Adjunctive Therapy for Psoriasis

Tazarotene 0.1% + medium/high-potency TCS for 8-16 weeks provides synergistic effect and prolonged remission (Strength A) 2

Critical Caveats for Psoriasis Treatment

• Avoid salicylic acid with calcipotriene - acid pH inactivates calcipotriene 2
• Apply vitamin D analogues AFTER phototherapy if combining treatments - prevents UVA inactivation and UVB blocking 2
• Duration limits for TCS monotherapy: Maximum 4 weeks for Class I-III TCS on non-intertriginous areas without supervision 2
• Long-term use (>12 weeks): Requires careful physician supervision due to atrophy risk 2

Practical Application Guidance

Ointment vs. Other Formulations

While the question asks specifically about ointments, the evidence shows:

• Ointments provide superior occlusion and penetration for thick, chronic plaques
• Creams (e.g., calcipotriene/betamethasone cream) show high patient satisfaction and adherence due to cosmetic acceptability 4
• Foams and gels are preferred for scalp application 2

Maintenance Strategy

For both conditions:

• Gradual tapering after clinical improvement (not abrupt withdrawal to avoid rebound) 2
• Proactive maintenance with intermittent application to previously affected sites 1
• Consider steroid-sparing agents (tacrolimus, pimecrolimus) for long-term facial/intertriginous use 2

When Initial Topical Therapy Fails

If optimized topical therapy fails after 4-8 weeks 1:

• Reconsider diagnosis (contact dermatitis, cutaneous lymphoma for eczema)
• Escalate to phototherapy or systemic agents
• Ensure proper application technique and adherence